ARID2 and melanoma: ARID2 mutation is a potential biomarker positively indicating ICIs effectiveness in melanoma patients.[23–25] Considering that biomarkers are often complex and non-binary, and we only see part of the picture since the potential heterogeneity has not been evaluated, therefore, it is overly simplistic to seek predictive power from a single biomarker.